2 February 2013
Financial support for Theradiag comes as part of CaReNA, a large-scale project to develop RNA-targeting therapeutics and diagnostics for HIV/AIDS and obesity.
Theradiag (Marne La Vallee, France), a company specializing in theranostics and in vitro diagnostics, has recently announced that it will receive €1.2 million in financial support from French Innovation Agency Oséo (Maisons-Alfort, France) for the company’s participation in CaReNA.
CaReNa is a collaborative effort involving project-lead Splicos (Montpellier, France), a company focused on alternative RNA splicing, Theradiag, and the French National Center for Research and Science (CNRS). The project’s goal is to develop RNA-targeting therapeutic and diagnostic solutions in the treatment of HIV/AIDS and obesity. As part of the venture, Theradiag are tasked with developing and implementing four new diagnostic kits.
Two of these kits will be developed as companion diagnostics to Splicos’ therapeutics, for the treatment of HIV/AIDS and for the monitoring of diabetes and associated metabolic disorders. These will be implemented from the clinical development phase in order for physicians to optimize patient care as part of a theranostic strategy. A third kit will be developed for the early monitoring of HIV infection and disease evolution, while a fourth test will allow for the assessment of patient response and/or resistance to antiretroviral treatments through the quantification of predicting miRNAs.
Michel Finance, Chief Executive Officer of Theradiag, commented on the announcement, “We are thrilled by this partnership with Splicos and CNRS. The support granted by Oséo for this project lends validation to our strategic development goal based on providing innovative theranotics through our miRNA platform. This new financing will allow us to expand our theranostic range with four new molecular biology/miRNA diagnostic kits, adding on to the existing seven blood-test kits of the Lisa Tracker portfolio. With these new kits, we will be able to tap into the broad diagnostic markets of HIV/AIDS and metabolic disorders.”